Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. The growth was primarily driven by about $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%.
The company noted that TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. This broadening coverage is likely to enhance patient access and drive further adoption of the drug.
Beyond commercial progress, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments underscore the company's commitment to addressing high unmet medical needs in central nervous system and immunology areas.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its current resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as the company scales TONMYA and progresses its pipeline.
The strong performance of TONMYA is particularly notable as it is the first new treatment for fibromyalgia in more than 15 years. Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties, affecting millions of people worldwide. The drug's increasing prescription numbers and expanding insurance coverage suggest growing acceptance among physicians and patients.
Tonix's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. The company is also evaluating TONMYA's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Its CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare genetic disorder. In immunology, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
These pipeline programs highlight Tonix's strategic focus on areas with significant unmet needs. The company's ability to generate revenue from TONMYA while advancing multiple clinical candidates positions it for potential long-term growth. Investors and industry observers will be watching for further updates on TONMYA's market uptake and the progress of its clinical trials.
For more information, visit the company's newsroom at https://nnw.fm/TNXP.
